89bio reports second quarter 2024 financial results and corporate updates

–the phase 3 enlighten-fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (mash) and the phase 3 enlighten-cirrhosis trial in patients with compensated cirrhosis (f4) are enrolling patients–
ETNB Ratings Summary
ETNB Quant Ranking